Healius ASX:HLS Stock Report

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Down from AU$4.64, the current price target is an average from 15 analysts. New target price is 15% above last closing price of AU$3.75. Stock is down 13% over the past year. The company is forecast to post earnings per share of AU$0.50 for next year compared to AU$0.11 last year.

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Healius Limited (ASX:HLS) is understood to have been eyeing its rival Integral Diagnostics Limited (ASX:IDX) of late for a buyout. It comes as part of its plans to become a serious contender in the pathology and diagnostic imaging arena. However, sources say that while Integral has been of interest, the share price changes in both stocks makes a deal difficult for Healius right now, and it is expected to keep a watching brief should the situation change. The Healius share price has fallen since the start of the year, and while Integral's share price is down from the start of the year, it needs to fall further for a deal to make sense. Healius earlier told the market that it has the capital flexibility to pursue acquisitive growth and was cashed up after selling its medical centre unit in 2020 to BGH Capital for $500 million. Healius is believed to be keeping a close watch on Integral as it looks to sell its day surgery business through advisory firm Gresham. It recently sold its Adora fertility unit. But shareholders did not back the offer, which required a 90% take-up rate.

Consensus EPS estimates fall by 13%

The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from AU$2.43b to AU$2.37b. EPS estimate also fell from AU$0.57 per share to AU$0.50 per share. Net income forecast to shrink 6.6% next year vs 10% growth forecast for Healthcare industry in Australia . Consensus price target down from AU$4.64 to AU$4.33. Share price fell 13% to AU$3.73 over the past week.